NEW YORK – Life science materials firm Biosynth Carbosynth said Wednesday that it has acquired Aalto Bio Reagents, a provider of reagents to the in vitro diagnostic and vaccine development industry, for an undisclosed sum.
Staad, Switzerland-based Biosynth said that the acquisition would broaden its offerings to the IVD industry, noting that Aalto’s portfolio includes a range of proteins, antigens, antibodies, and biospecimens used by diagnostics and vaccine development firms.
“This acquisition marks the next phase of our ambitious journey to become a leading global supplier and partner to the biopharma and diagnostics industries,” Urs Spitz, Biosynth’s president and CEO, said in a statement. “It allows us to offer an expanded range of products to our IVD customers including complex biochemicals, peptides, and biological materials.”
“Aalto’s industry-leading products and key focus on emerging disease are an excellent fit with Biosynth’s products, and we see huge opportunities for the platform to be at the forefront of developing new innovative products and supplying our customers with an even greater scale and diversity of products they need to solve the diseases of the future,” Aalto CEO Philip Noone added in a statement.
Financial and other terms of the deal were not disclosed.